BillionToOne, Inc. (BLLN)
About BillionToOne, Inc.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $305.1M
- Net income
- $7.5M
- Total assets
- $632.7M
- Market cap
- $4.5B
- Gross margin
- 68.3%
- Operating margin
- 5.3%
- Net margin
- 2.4%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $305.1M
- Cost of revenue
- $96.7M
- Gross profit
- $208.5M
- Operating expenses
- $192.4M
- Operating income
- $16.0M
- Income tax
- $305.0K
- Net income
- $7.5M
- EPS (basic)
- $0.18
- EPS (diluted)
- $0.14
Balance sheet
- Total assets
- $632.7M
- Current assets
- $560.6M
- Total liabilities
- $152.5M
- Current liabilities
- $48.0M
- Shareholders’ equity
- $480.1M
Cash flow
- Operating cash flow
- $24.6M
- Investing cash flow
- -$8.9M
- Financing cash flow
- $288.8M
- Net cash flow
- $304.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $4.5B
- P/E ratio
- 900.6
- EPS (diluted)
- $0.14
- Shares outstanding
- 35.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 6, 2025
BillionToOne, Inc. (BLLN) Stock Price
- Profitable — net income of $7.5M in FY2025.
- Gross margin of 68.3%, net margin 2.4%.
- Trading 5% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 900.6.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BillionToOne, Inc..
Write a review
News about BillionToOne, Inc.
News & sentiment via Polygon.io
BillionToOne, Inc.: frequently asked questions
Is BillionToOne, Inc. an American company?
BillionToOne, Inc. is a US-based company headquartered in Menlo Park, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is BillionToOne, Inc. headquartered?
BillionToOne, Inc. is headquartered in Menlo Park, California, United States.
Is BillionToOne, Inc. publicly traded?
Yes — BillionToOne, Inc. is a publicly traded company. Its stock trades under the ticker symbol BLLN on the NASDAQ.
What does BillionToOne, Inc. do?
BillionToOne, Inc. is an American Medical Devices company in the Health & Beauty sector.
When was BillionToOne, Inc. founded?
BillionToOne, Inc. was founded in 2016.
